CRIS

Curis (CRIS)

About Curis (CRIS)

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Details

Daily high

$1.42

Daily low

$1.33

Price at open

$1.35

52 Week High

$4.50

52 Week Low

$1.02

Market cap

17.5M

Dividend yield

0.00%

Volume

102,891

Avg. volume

108,287

P/E ratio

-.37

Curis News